Dry Eyes

Dry eye disease (DED) is defined by the TFOS DEWS II consensus as a multifactorial disease of the tears and ocular surface, resulting in symptoms of discomfort, visual disturbance, and tear film instability, with potential damage to the ocular surface. It is accompanied by increased tear film osmolarity and inflammation of the ocular surface, and — for the first time in this 2017 update — neurosensory abnormalities are included in the definition, reflecting how directly the corneal nerves are involved in symptom generation.^[1]

Contemporary classification places every case somewhere on a continuum between two mechanisms rather than in one fixed bin. Aqueous-deficient dry eye reflects insufficient tear volume from lacrimal gland dysfunction (Sjögren-associated or non-Sjögren). Evaporative dry eye reflects excessive tear evaporation despite roughly normal tear production — most often from meibomian gland dysfunction (MGD), where a deficient or abnormal lipid layer allows the aqueous layer beneath it to evaporate too quickly, though inadequate lid closure, reduced blink rate, and ocular surface disease also contribute. Elements of both mechanisms coexist in most real patients, and evaporative disease — driven by MGD — is now recognized as the more common of the two, whether it occurs alone or alongside a degree of aqueous deficiency.^[1][2]

The tear film's three layers, outermost to innermost: lipid (meibomian gland secretions), aqueous (lacrimal gland), and mucin (conjunctival goblet cells) over the corneal epithelium. Deficiency or dysfunction of any layer — most often the lipid layer in meibomian gland dysfunction — produces dry eye disease. (Vinne2, CC BY-SA, Wikimedia Commons)

DED is genuinely common: global prevalence estimates range from about 5% to 50% depending on the population studied and the diagnostic criteria applied, prevalence rises with age beyond the fifth decade of life, and women are more often affected than men.^[3] A history of lid, ocular, or refractive surgery; age over 40; female sex; certain medications and systemic diseases; smoking; computer vision syndrome; and frequent exposure to harsh environments are the risk factors most consistently associated with DED — see Etiology and Risk Factors.^[4]

Symptoms

Patients describe DED in strikingly consistent terms: grittiness, burning, stinging, a foreign-body or sandy sensation, mild redness, and fluctuating vision that clears with blinking — the tear film briefly restoring optical quality after each blink before breaking up again. Symptoms are often worse later in the day, with prolonged visual tasks (reading, screens), and in dry, windy, air-conditioned, or heated environments.^[4][1]

Paradoxically, DED can also present with watery eyes. A destabilized, hyperosmolar tear film irritates the ocular surface enough to trigger reflex tearing — a compensatory response that can overwhelm normal drainage and present as epiphora rather than dryness. Because of this, "watery eyes" is one of the four screening questions used to identify DED, not a finding that rules it out.^[4]

Presentation differs somewhat by mechanism

The four-question screen

Given how common and variable DED is, the Canadian Association of Optometrists' national guidelines treat almost every adult presenting for eye care as a DED suspect until proven otherwise, and use four simple case-history questions as an efficient screen:^[4]

1. Do your eyes feel uncomfortable?
2. Do you have watery eyes?
3. Does your vision fluctuate, especially in a dry environment?
4. Do you use eye drops?

A "yes" to any of these should prompt one further question — do you have dry mouth? — since dry eye plus dry mouth together should raise suspicion for Sjögren syndrome and prompt consideration of referral (for example, to a rheumatologist); ocular symptoms have many other mimics as well, so a systematic screen and, where indicated, a full workup are what actually differentiate DED from its look-alikes rather than symptoms alone (see Assessment and Diagnosis).^[4]

• Age over 40 years, with risk continuing to rise with age thereafter.^[4][3]
• Female sex — women are more often affected than men, related in part to androgen/estrogen imbalance and menopause.^[4][3]
• A history of lid, ocular, or refractive surgery (including LASIK, which transiently reduces corneal sensation).^[4]
• Contact lens wear — a well-established risk factor for dry eye symptoms and, independently, for more serious contact-lens-associated corneal complications; see Red Flags for Referral for the urgent-referral distinction.^[4]
• Computer vision syndrome and heavy use of computers or hand-held devices, which reduce blink rate and completeness and widen the interpalpebral area exposed to evaporation.^[4]
• Smoking, and frequent exposure to harsh environments — dry air, wind, cooling and heating units, and air travel.^[4]
• Continuous positive airway pressure (CPAP) therapy for sleep apnea, when air escapes a poorly fitted mask across the ocular surface overnight.^[4]
• Ocular rosacea and anterior blepharitis, strongly associated with meibomian gland dysfunction.^[4]
• A broad range of systemic diseases — most importantly Sjögren syndrome, rheumatoid arthritis, thyroid disease, diabetes mellitus, and graft-versus-host disease, also androgen deficiency, chronic hepatitis C, diabetes insipidus, pemphigoid, primary biliary cirrhosis, psoriasis, scleroderma, systemic lupus erythematosus, Stevens-Johnson syndrome, and vitamin A deficiency.^[4]
• A large number of systemic medications with the potential to induce or exacerbate DED — see the table below. These act through several mechanisms: anticholinergic and antihistaminic drugs reduce aqueous and mucin secretion by blocking muscarinic receptors on the lacrimal gland and conjunctival goblet cells; isotretinoin shrinks the meibomian glands and reduces meibum production, thinning the lipid layer; beta-blockers (both oral agents and topical glaucoma drops) reduce aqueous tear production; and several other classes contribute through overlapping anticholinergic or secretory effects.^[5][6]

^[4] A 2018 correction to the most widely cited medication-induced dry eye review reclassified several drugs into their correct pharmacologic categories — a reminder to confirm a suspected culprit medication's actual drug class (and this platform's own Drug Database entry) rather than relying on an older secondary list from memory.^[6][5]

The pharmacist's role: screen, then know when to refer for the full workup

The Canadian Association of Optometrists' national guidelines describe a practical, staged approach that translates well to a community pharmacy consult: a quick, selective screen using the four case-history questions above, evaluation of risk factors, and — where an eye care practitioner is available to perform it — a brief screening examination, before a patient is referred for a full, more time-intensive DED workup.^[4]

The screening examination (performed by an optometrist or ophthalmologist)

1. Evaluate facial symmetry, eyelids, lashes, blink, and lid closure — looking for irregularities, crusting, redness, and other evidence of lid disease, and specifically for rosacea, which frequently has ocular manifestations that can precede its dermatologic signs by years.^[4]
2. Tear film breakup time (TBUT) — fluorescein is instilled, the patient blinks normally, and the tear film is observed under a cobalt blue filter for the time until the first dry spot appears; a result under 10 seconds raises suspicion for DED. (A fluorescein/anesthetic combination is avoided for this test, since anesthetic drops trigger reflex tearing and invalidate the result.)^[4]
3. Fluorescein corneal staining — evaluated under the same cobalt filter; staining associated with DED is typically most evident in the lower cornea and tends to be confluent.^[4]

A Schirmer test (with or without topical anesthetic) is often added to assess aqueous tear volume directly: a strip is placed at the junction of the middle and lateral thirds of the lower lid for 5 minutes, and wetting under 10 mm suggests aqueous deficiency, with wetting under 5 mm suggesting more severe deficiency. These bedside tests remain the practical mainstay of a primary-care-level DED workup even as more specialized point-of-care diagnostics become available in some specialist settings.^[7]

Ruling out mimics

Ocular discomfort has many causes besides DED, and a systematic screen is what actually distinguishes them.

^[4]

Screening for Sjögren syndrome

Prolonged symptoms, dry mouth, low tear flow, and ocular surface staining together should prompt consideration of Sjögren syndrome. Two published criteria sets are used to confirm the diagnosis, both requiring specialist input (rheumatology, and often a minor salivary gland biopsy or serology):

^[4] A positive screen is a referral trigger, not a pharmacy-level diagnosis — see Red Flags for Referral.

• Relieve symptoms and restore a stable, adequately lubricating tear film.
• Identify whether the presentation is predominantly aqueous-deficient, evaporative/MGD, or — as in most patients — a mix of both, since this shapes which supportive measures matter most.
• Identify and address modifiable contributors: environmental exposure, screen habits, contact lens wear and hygiene, and medications with anticholinergic or antihistaminic effects.
• Protect the ocular surface from mechanical and inflammatory damage, and prevent progression to more severe or recalcitrant disease.
• Break the self-perpetuating cycle of tear hyperosmolarity and ocular surface inflammation that drives chronic disease, once episodic measures alone are insufficient.
• Match the intensity of therapy to disease tier — episodic, chronic, or recalcitrant — rather than defaulting every patient to the same over-the-counter recommendation indefinitely.
• Screen for, and refer, an underlying systemic cause — most importantly Sjögren syndrome — rather than treating dry eye in isolation when sicca symptoms or other systemic clues are present.
• Set realistic expectations: DED is usually a chronic, relapsing-remitting condition that is managed rather than cured, and anti-inflammatory therapies can take weeks to months to show their full effect.

First-line for everyone: tear supplementation

Tear supplements/lubricants are the mainstay of treatment across the full spectrum of DED and the appropriate starting point for essentially every patient, including while a more chronic or systemic cause is being worked up. There is evidence that regular use measurably improves ocular surface staining within about a month.^[4] Using an ocular lubricant more than 4 times a day should prompt a switch to a non-preserved (preservative-free) product to reduce the risk of toxic adverse effects on the ocular surface from repeated preservative exposure — preservative-free products should also be favoured whenever another topical ocular medication is being used concurrently.^[4] See Pharmacologic Treatment Options and Drug Tables for how to match a specific product's composition (osmolarity, preservative status, viscosity, and lipid content) to the patient's presentation.

Stepping up to chronic-disease (anti-inflammatory) management

Even with diligent use of tear supplements, hot compresses, and lid hygiene, many patients experience persistent or progressive symptoms and signs. This reflects, at least in part, a self-perpetuating cycle in which abnormal tear secretion increases tear film osmolarity, which in turn stimulates production of inflammatory mediators on the ocular surface — inflammation is the core mechanism sustaining chronic DED regardless of the initial cause, so strategies aimed at arresting that cycle are central to chronic-disease management.^[4]

Anything but clearly episodic initiate a short-term topical corticosteroid trial — loteprednol etabonate 0.5% is the usual first choice, given a similar efficacy but a more favourable safety profile (lower risk of intraocular pressure elevation, cataract, and delayed healing) than older ketone-based steroids.^[4] A preservative-free option, methylprednisolone acetate 1%, is reasonable for a patient who cannot tolerate loteprednol, and has shown favourable results specifically in Sjögren-associated DED.^[4] Generally, loteprednol 0.5% is given 4 times daily for 2-4 weeks (or sometimes longer), during which efficacy, intraocular pressure, and side effects are evaluated; if symptoms or signs improve, topical cyclosporine 0.05% is initiated and the corticosteroid is continued concurrently at a reduced frequency for another 2-4 weeks to ease the transition, before tapering to cyclosporine monotherapy.^[4] See the Clinical Decision Algorithm for the full follow-up schedule (1-2 weeks, 2-4 weeks, 3 months, 6 months).

Cyclosporine 0.05% ophthalmic modulates T-cell-mediated ocular surface inflammation; some patients report symptomatic improvement within a couple of weeks, but a demonstrable effect on signs can take 3 months or longer, and patients with severe chronic or recalcitrant disease can take up to a full year to show real improvement — set this expectation explicitly at the outset, since abandoning therapy after only a few weeks is a common and avoidable reason for perceived treatment failure. The main adverse effect is transient burning on instillation, reported in roughly 17% of patients in clinical trial (about 10% more than with vehicle alone); cyclosporine is not associated with steroid-related ocular adverse effects, which is one of its key advantages for a therapy meant to be used long-term.^[4]

Lifitegrast 5% ophthalmic solution is a lymphocyte function-associated antigen-1 (LFA-1) antagonist, approved by Health Canada in 2018 (after the 2014 Canadian guideline above was published) for the signs and symptoms of DED; it blocks the LFA-1/ICAM-1 interaction that drives T-cell-mediated inflammation on the ocular surface, is dosed twice daily, and — unlike cyclosporine — does not require a corticosteroid bridge to initiate. It is a reasonable alternative or add-on where cyclosporine is not tolerated or is insufficient; the most common adverse effects are instillation-site irritation and an altered, typically bitter or unusual taste (dysgeusia) shortly after instillation.^[2]

Supportive chronic-tier measures

Oral tetracycline (usually doxycycline 40-50 mg once daily) or, where tetracyclines are contraindicated, a macrolide (erythromycin or azithromycin), is used for MGD and ocular/facial rosacea — beyond their antibacterial effect, these drugs inhibit bacterial lipases (reducing free fatty acids in meibomian secretions) and have direct anti-inflammatory effects, including inhibition of matrix metalloproteinases.^[4] Lacrimal occlusion (punctal plugs) is considered once ocular surface inflammation is reasonably controlled — except in severe aqueous deficiency, where occlusion may be needed earlier to facilitate tear retention despite incompletely controlled inflammation; see Non-Pharmacologic Management for indications and contraindications.^[4]

• Hot compresses are a mainstay for MGD: the melting point of meibomian lipid secretions is elevated in MGD (32-35°C) compared to unaffected glands, and a 40°C compress applied for at least 4 minutes measurably increases tear film lipid layer thickness, with further improvement after 15 minutes. Daily use for a few weeks to months is typical, then a maintenance regimen of 2-3 times weekly; consistent daily use with a simple face cloth is time-intensive and adherence is often the limiting factor, so purpose-made reusable compress devices are a reasonable alternative.^[4]
• Lid hygiene is recommended for anterior blepharitis — gentle daily cleansing of the lids and lashes to remove debris and prevent it from contacting and irritating the ocular surface; tea tree oil-containing products (shampoos, wipes, in-office solutions) are increasingly used specifically for blepharitis associated with Demodex folliculorum.^[4]
• Moisture chamber spectacles are a highly effective but underused option for increasing ambient humidity at the ocular surface and reducing evaporation; patients often do well starting with wraparound sunglasses outdoors before moving to clear moisture-chamber glasses for indoor and low-light use. A good fit is essential to comfort and effectiveness.^[4]
• Environmental modification — a small humidifier at home or in the office measurably improves symptoms, especially where air conditioning or heating runs for extended periods; protect the eyes from direct air movement (fans, vents) with moisture-chamber glasses or, at minimum, ordinary spectacles; minimize or protect against airplane and car-travel air exposure.^[4]
• Computer/device habits — position screens below the primary line of sight to reduce lid aperture width and evaporative exposure, and consciously increase blink rate and completeness during extended visual tasks.^[4]
• Contact lens modification — switching to daily disposable lenses, reducing wear time, or reviewing lens solutions can meaningfully reduce symptoms in contact-lens-related DED.^[4]
• CPAP mask fit — for patients on CPAP therapy whose morning DED symptoms worsen from air escaping a poorly fitted mask, a flexible ocular shield or careful mask refitting can help without compromising the mask seal.^[4]
• Sleep masks or lid taping for patients with inadequate lid closure during sleep (nocturnal lagophthalmos) — with explicit instruction on proper technique to avoid corneal trauma.^[4]
• Essential fatty acid (omega-3) supplementation has anti-inflammatory effects and is a reasonable adjunct, though the optimal form and dosing regimen are still not firmly established; if gamma-linolenic acid (an omega-6 found in evening primrose and borage oil) is used, it should be combined with EPA/DHA in at least a 1:1 ratio, since GLA alone, without adequate omega-3 co-administration, can have a pro-inflammatory effect.^[4]
• Medication review — flag a suspected culprit medication (see Etiology and Risk Factors) for discussion with the prescriber, but do not recommend stopping an essential medication solely because of its dry eye potential; second-generation antihistamines are a reasonable substitute for first-generation agents where an antihistamine is genuinely needed. Alcohol consumption and cigarette smoke exposure are avoidable environmental triggers worth addressing directly with the patient.^[4]
• In-office meibomian gland expression (manual, or thermal pulsation systems) is both a diagnostic and therapeutic procedure that restores normal gland outflow; a single thermal-pulsation treatment can improve symptoms and objective signs for 9-12 months.^[4]
• Lacrimal occlusion (punctal plugs) reduces tear drainage, decreasing symptoms, reducing corneal staining, prolonging TBUT, and increasing goblet cell density. It is most appropriate for aqueous-deficient disease — generally considered for wetting under 15 mm, and especially under 10 mm, on tear-flow testing — and is also indicated in contact lens intolerance, filamentary keratitis, neurotrophic cornea, and systemic diseases such as Sjögren syndrome, Stevens-Johnson syndrome, and graft-versus-host disease. It is contraindicated with an occluded canaliculus, active canaliculitis, allergy to the plug material, or frank punctal ectropion; the most common complication is spontaneous extrusion requiring replacement, with internal migration, inability to irrigate intracanalicular plugs, and pyogenic granuloma formation reported less often.^[4]

Pregnancy

Hormonal shifts in pregnancy can worsen DED. Ocular lubricants are first-line and considered safe throughout pregnancy. Data on topical corticosteroids, cyclosporine, and lifitegrast in pregnancy are limited; use only where the anticipated benefit clearly outweighs the uncertainty, and involve the prescriber. Avoid oral tetracyclines (doxycycline) in pregnancy given the risk of fetal tooth and bone effects — azithromycin or erythromycin are the reasonable alternatives when oral MGD/rosacea therapy is genuinely needed.

Breastfeeding

Ocular lubricants remain first-line and are not a concern during breastfeeding given negligible systemic absorption. Oral tetracyclines are still generally avoided; azithromycin is usually considered compatible with breastfeeding, but confirm specifics against the product's own Drug Database entry before recommending it.

Pediatrics

DED is less common in children but does occur — heavy screen time, allergic conjunctivitis, and, in teenagers, contact lens wear are the most relevant contributors. Doxycycline is avoided under 8 years (permanent tooth staining) — a macrolide is the reasonable alternative when oral MGD therapy is needed. Persistent pediatric DED, or DED occurring alongside other ocular or systemic findings, warrants referral to pediatric ophthalmology rather than open-ended self-care.

Older adults

Age over 40 is itself one of the strongest risk factors, and prevalence continues rising through later decades.^[3] Polypharmacy substantially raises the odds that one or more medications on the list in Etiology and Risk Factors is contributing — a full medication review is disproportionately useful in this group. Comorbid blepharitis and MGD are common; balance overall anticholinergic burden across a patient's full medication list rather than focusing on any single agent in isolation.

Menopause and hormonal status

Androgen/estrogen imbalance around menopause is a recognized contributor to DED, and women are more affected than men overall.^[4][3] Notably, estrogen supplementation/hormone replacement therapy itself appears on the medication list associated with inducing or worsening DED — this is worth specifically raising with a patient starting hormone therapy who develops new ocular symptoms, without implying it should be stopped without discussion with the prescriber.^[4]

Contact lens wearers

Discuss wear-schedule and solution modification, and daily disposable lenses, as first steps for contact-lens-related dryness (see Non-Pharmacologic Management). Scleral lenses are reserved for severe or recalcitrant disease and require specialist fitting; they are not a first-line contact lens recommendation for ordinary DED. Any red, painful contact-lens-wearing eye is a red flag requiring the patient to stop lens wear and be assessed urgently — see Red Flags for Referral.

Sjögren syndrome and other autoimmune/systemic disease

Patients with confirmed or suspected Sjögren syndrome, rheumatoid arthritis, graft-versus-host disease, or other significant systemic contributors typically sit in the chronic or recalcitrant management tier from the outset, need coordinated care with rheumatology or the relevant specialist, and are the population for whom preservative-free methylprednisolone, pilocarpine for dry mouth, and — in recalcitrant disease — systemic immunosuppressive therapy are most often used.^[4]

Renal and hepatic impairment

Topical ocular therapies (lubricants, loteprednol, methylprednisolone, cyclosporine, lifitegrast) have minimal systemic absorption and generally require no renal or hepatic dose adjustment. For oral doxycycline or azithromycin used for MGD/rosacea, apply the usual renal/hepatic dosing precautions for those agents — confirm against a standard dosing reference or the product's own Drug Database entry.

Follow-up needs differ meaningfully by tier. For a patient started on first-line tear supplementation and modifiable-risk-factor management (episodic tier), reassess in a few weeks; no improvement, or worsening, despite genuinely optimized self-care is the trigger to refer for a full DED workup rather than simply recommending a stronger or more frequent product indefinitely.^[4]

For a patient starting the corticosteroid-to-cyclosporine transition (chronic tier), the Canadian guideline's protocol sets a concrete follow-up cadence:^[4]

• 1-2 weeks — assess symptom and sign response to the corticosteroid; if responding, initiate cyclosporine at reduced steroid frequency; if not responding, especially in moderate-to-severe disease, consider extending the steroid trial to 4 weeks.
• 2-4 weeks — if there has been a positive response, taper or withdraw the corticosteroid; if the patient reports marked stinging with cyclosporine, continue the steroid a little longer while monitoring for adverse effects, including intraocular pressure.
• 3 months — monitor for resolution of symptoms and signs; a brief pulse of corticosteroid can be considered if breakthrough symptoms require it.
• 6 months and ongoing — continue monitoring for improvement and adverse effects; review the whole regimen at each visit (diagnostic findings, lid disease, allergy, patient adherence, and overall resolution) rather than assuming the initial plan still fits.

Any patient on a topical corticosteroid, at any point, needs a defined follow-up for intraocular pressure and lens clarity — this is not optional once a steroid trial is started.^[4] Patients on cyclosporine or lifitegrast need their expectations reinforced at each visit (weeks to months for full effect) so that a slow, real response is not mistaken for treatment failure. For lacrimal occlusion, ask about epiphora (over-retention) and check for spontaneous extrusion at follow-up. Reconcile the full medication list at every visit, flagging any newly added or discontinued drug from the Etiology and Risk Factors list without unilaterally recommending discontinuation of anything the prescriber has not reviewed.

1. No improvement after several weeks of genuinely optimized episodic management (correct lubricant selection and frequency, modifiable risk factors addressed): refer for a full DED workup rather than simply escalating lubricant use further.
2. Persistent symptoms or signs — especially visible inflammation or staining — despite optimized episodic measures: step up to the chronic tier (corticosteroid trial transitioning to cyclosporine or lifitegrast), rather than repeating episodic measures indefinitely.
3. No response to the corticosteroid trial after 2-4 weeks, particularly in moderate-to-severe disease: consider extending the trial to 4 weeks before concluding it has failed.
4. Intolerable burning with cyclosporine: this is usually transient in the first weeks — continue if tolerable, or switch to lifitegrast as an alternative anti-inflammatory rather than abandoning long-term therapy altogether.
5. Severe aqueous deficiency not adequately controlled despite therapy (very low tear-flow test results): consider earlier lacrimal occlusion even before inflammation is fully controlled, rather than waiting for the usual sequence.
6. Recalcitrant despite maximal, adherent chronic-tier therapy: refer to ophthalmology for recalcitrant-tier options (scleral lenses, autologous serum, systemic secretagogues or immunosuppressants) rather than repeating the same regimen.
7. A positive Sjögren screen (dry eye plus dry mouth) not yet formally worked up: refer to rheumatology in parallel with continued DED management — do not wait for ocular findings alone to drive that referral.
8. A new red-flag finding appears at any point in this pathway (photophobia with pain, a red painful contact-lens-wearing eye, sudden vision change, visible corneal pathology): stop stepwise escalation and refer urgently — see Red Flags for Referral.

• Recommending a preserved multidose lubricant for frequent (more than 4 times daily) use instead of switching to a preservative-free product.
• Treating dry eye as purely an aqueous-deficiency problem and skipping hot compresses and lid hygiene — evaporative disease driven by meibomian gland dysfunction is the more common mechanism.
• Recommending a vasoconstrictor "redness reliever" drop for dry-eye-related redness — it masks the sign without treating the underlying dryness and can cause rebound hyperemia with regular use.
• Not asking the four screening questions, plus the dry-mouth follow-up, in a patient with vague ocular complaints, and missing dry eye disease as the likely explanation by default.
• Overlooking the medication list — not recognizing an antihistamine-, anticholinergic-, or isotretinoin-heavy regimen as a genuine contributor.
• Recommending a patient stop an essential systemic medication solely because it appears on the dry-eye-inducing drug list, without involving the prescriber.
• Starting a topical corticosteroid without a defined follow-up and taper/transition plan, or without a plan to monitor intraocular pressure.
• Placing punctal plugs before ocular surface inflammation is reasonably controlled in a patient whose disease is not severely aqueous-deficient — this can trap inflammatory mediators against the surface instead of relieving symptoms.
• Missing a positive dry-eye-plus-dry-mouth screen as a Sjögren syndrome clue and not raising rheumatology referral.
• Treating a red, painful eye in a contact lens wearer as ordinary dry eye rather than an urgent rule-out for microbial keratitis.
• Assuming a child or teenager's eye symptoms cannot be dry eye disease despite heavy screen time or contact lens wear.
• Recommending oral doxycycline for MGD/rosacea in a pregnant patient or a child under 8 without considering a macrolide alternative.
• Abandoning cyclosporine or lifitegrast after only a few weeks without having set the realistic weeks-to-months timeline for effect at the outset.

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Ocular Lubricants / Tear Supplements

First-line across every DED tier. Match composition to presentation: hyaluronate/polymer-containing products for lid-wiper-type dryness, lipid-based/emulsion products for evaporative/MGD-associated disease, and low-viscosity drops by day with a more viscous gel or ointment at night. Switch to a preservative-free product once use exceeds 4 times daily or alongside other topical ocular medications.

Short-Term Anti-Inflammatory Therapy (Corticosteroid Trial)

A defined 2-4 week trial that both treats and confirms the inflammatory component of chronic DED, and eases the transition to long-term cyclosporine. Every course needs a scheduled follow-up for intraocular pressure and lens clarity.

Long-Term Anti-Inflammatory Therapy

The mainstay of chronic-tier DED management once the corticosteroid trial confirms an inflammatory component. Set realistic timelines: weeks for symptomatic benefit, 3 months or longer for a demonstrable effect on signs, up to a year in severe or recalcitrant disease.

Oral Adjuncts for Meibomian Gland Dysfunction / Ocular Rosacea

Beyond antibacterial effect, these inhibit bacterial lipases and matrix metalloproteinases in meibomian secretions. Avoid tetracyclines in pregnancy and in children under 8 years.

Systemic Secretagogue (Sjögren-Associated Dry Mouth)

Treats the oral sicca component in Sjögren syndrome; does not directly treat the ocular component. Titrate slowly — many patients cannot tolerate the full labelled dose but still benefit from a lower one.